Review



goat anti mouse cd30 tnfrsf8 antibody  (R&D Systems)


Bioz Verified Symbol R&D Systems is a verified supplier
Bioz Manufacturer Symbol R&D Systems manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 94
      Buy from Supplier

    Structured Review

    R&D Systems goat anti mouse cd30 tnfrsf8 antibody
    Goat Anti Mouse Cd30 Tnfrsf8 Antibody, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+cd30/Mouse+CD30%2FTNFRSF8+Antibody/pmc13101361-74-17-26
    Average 94 stars, based on 1 article reviews
    goat anti mouse cd30 tnfrsf8 antibody - by Bioz Stars, 2026-09
    94/100 stars

    Images

    Related Articles

    Saline:

    Article Title: CD30 knockout attenuates experimental colitis by reducing inflammatory cytokine production
    Article Snippet: Equal amounts of protein (30 μg) were separated by 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis and transferred to polyvinylidene difluoride membranes (Millipore, Burlington, MA, USA) using a Trans-Blot system (Bio-Rad, Hercules, CA, USA). .. Membranes were blocked with 5% non-fat milk (BD Biosciences) in Tris-buffered saline with 0.1% Tween-20 (TBST) for 1 h at room temperature and incubated overnight at 4 °C with following primary antibodies (1:1000 dilution): anti-CD30 (Cat. No. AF852; R&D Systems), anti-T-bet (Cat. No. ab91109; Abcam, Cambridge, MA, USA), anti-IFN-γ (Cat. No. ab9657; Abcam), anti-STAT4 (Cat. No. 2653; Cell Signaling Technology, Danvers, MA, USA), anti-phospho-STAT4 (Tyr693) (Cat. No. 4134; Cell Signaling Technology), anti-NF-κB p65 (Cat. No. 8242; Cell Signaling Technology), anti-phospho-NF-κB p65 (Ser536) (Cat. No. 3033; Cell Signaling Technology), anti-IκBα (Cat. No. 4814; Cell Signaling Technology), anti-phospho-IκBα (Ser32) (Cat. No. 2859; Cell Signaling Technology), and anti-β-actin (Cat. No. 4970; Cell Signaling Technology). .. After washing with TBST, membranes were incubated with horseradish peroxidase-conjugated secondary antibodies (Cat. No. 7074 for anti-rabbit IgG, Cat. No. 7076 for anti-mouse IgG; Cell Signaling Technology, 1:5000 dilution) for 1 h at room temperature.

    Article Title: CD30 knockout attenuates experimental colitis by reducing inflammatory cytokine production.
    Article Snippet: Equal amounts of protein (30 μg) were separated by 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis and transferred to polyvinylidene difluoride membranes (Millipore, Burlington, MA, USA) using a Trans-Blot system (Bio-Rad, Hercules, CA, USA). .. Membranes were blocked with 5% non-fat milk (BD Biosciences) in Tris-buffered saline with 0.1% Tween-20 (TBST) for 1 hour at room temperature and incubated AR TIC LE IN PR ES S overnight at 4°C with following primary antibodies (1:1000 dilution): anti-CD30 (Cat. No. AF852; R&D Systems), anti-T-bet (Cat. No. ab91109; Abcam, Cambridge, MA, USA), anti-IFN-γ (Cat. No. ab9657; Abcam), anti-STAT4 (Cat. No. 2653; Cell Signaling Technology, Danvers, MA, USA), anti-phospho-STAT4 (Tyr693) (Cat. No. 4134; Cell Signaling Technology), anti-NF-κB p65 (Cat. No. 8242; Cell Signaling Technology), anti-phospho-NF-κB p65 (Ser536) (Cat. No. 3033; Cell Signaling Technology), anti-IκBα (Cat. No. 4814; Cell Signaling Technology), anti-phospho-IκBα (Ser32) (Cat. No. 2859; Cell Signaling Technology), and anti-β-actin (Cat. No. 4970; Cell Signaling Technology). .. After washing with TBST, membranes were incubated with horseradish peroxidase-conjugated secondary antibodies (Cat. No. 7074 for anti-rabbit IgG, Cat. No. 7076 for anti-mouse IgG; Cell Signaling Technology, 1:5000 dilution) for 1 hour at room temperature.

    Incubation:

    Article Title: CD30 knockout attenuates experimental colitis by reducing inflammatory cytokine production
    Article Snippet: Equal amounts of protein (30 μg) were separated by 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis and transferred to polyvinylidene difluoride membranes (Millipore, Burlington, MA, USA) using a Trans-Blot system (Bio-Rad, Hercules, CA, USA). .. Membranes were blocked with 5% non-fat milk (BD Biosciences) in Tris-buffered saline with 0.1% Tween-20 (TBST) for 1 h at room temperature and incubated overnight at 4 °C with following primary antibodies (1:1000 dilution): anti-CD30 (Cat. No. AF852; R&D Systems), anti-T-bet (Cat. No. ab91109; Abcam, Cambridge, MA, USA), anti-IFN-γ (Cat. No. ab9657; Abcam), anti-STAT4 (Cat. No. 2653; Cell Signaling Technology, Danvers, MA, USA), anti-phospho-STAT4 (Tyr693) (Cat. No. 4134; Cell Signaling Technology), anti-NF-κB p65 (Cat. No. 8242; Cell Signaling Technology), anti-phospho-NF-κB p65 (Ser536) (Cat. No. 3033; Cell Signaling Technology), anti-IκBα (Cat. No. 4814; Cell Signaling Technology), anti-phospho-IκBα (Ser32) (Cat. No. 2859; Cell Signaling Technology), and anti-β-actin (Cat. No. 4970; Cell Signaling Technology). .. After washing with TBST, membranes were incubated with horseradish peroxidase-conjugated secondary antibodies (Cat. No. 7074 for anti-rabbit IgG, Cat. No. 7076 for anti-mouse IgG; Cell Signaling Technology, 1:5000 dilution) for 1 h at room temperature.

    Article Title: CD30 knockout attenuates experimental colitis by reducing inflammatory cytokine production.
    Article Snippet: Equal amounts of protein (30 μg) were separated by 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis and transferred to polyvinylidene difluoride membranes (Millipore, Burlington, MA, USA) using a Trans-Blot system (Bio-Rad, Hercules, CA, USA). .. Membranes were blocked with 5% non-fat milk (BD Biosciences) in Tris-buffered saline with 0.1% Tween-20 (TBST) for 1 hour at room temperature and incubated AR TIC LE IN PR ES S overnight at 4°C with following primary antibodies (1:1000 dilution): anti-CD30 (Cat. No. AF852; R&D Systems), anti-T-bet (Cat. No. ab91109; Abcam, Cambridge, MA, USA), anti-IFN-γ (Cat. No. ab9657; Abcam), anti-STAT4 (Cat. No. 2653; Cell Signaling Technology, Danvers, MA, USA), anti-phospho-STAT4 (Tyr693) (Cat. No. 4134; Cell Signaling Technology), anti-NF-κB p65 (Cat. No. 8242; Cell Signaling Technology), anti-phospho-NF-κB p65 (Ser536) (Cat. No. 3033; Cell Signaling Technology), anti-IκBα (Cat. No. 4814; Cell Signaling Technology), anti-phospho-IκBα (Ser32) (Cat. No. 2859; Cell Signaling Technology), and anti-β-actin (Cat. No. 4970; Cell Signaling Technology). .. After washing with TBST, membranes were incubated with horseradish peroxidase-conjugated secondary antibodies (Cat. No. 7074 for anti-rabbit IgG, Cat. No. 7076 for anti-mouse IgG; Cell Signaling Technology, 1:5000 dilution) for 1 hour at room temperature.



    Similar Products

    goat anti mouse cd30 tnfrsf8 antibody  (R&D Systems)
    94
    R&D Systems goat anti mouse cd30 tnfrsf8 antibody
    Goat Anti Mouse Cd30 Tnfrsf8 Antibody, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+cd30/Mouse+CD30%2FTNFRSF8+Antibody/pmc13101361-74-17-26
    Average 94 stars, based on 1 article reviews
    goat anti mouse cd30 tnfrsf8 antibody - by Bioz Stars, 2026-09
    94/100 stars
    		  Buy from Supplier
    anti cd30  (R&D Systems)
    94
    R&D Systems anti cd30
    Anti Cd30, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+cd30/Mouse+CD30%2FTNFRSF8+Antibody/pm41826817-101-40-44
    Average 94 stars, based on 1 article reviews
    anti cd30 - by Bioz Stars, 2026-09
    94/100 stars
    		  Buy from Supplier
    ai equibind different anti cd30 scfv clones  (Molecular Dynamics Inc)
    86
    Molecular Dynamics Inc ai equibind different anti cd30 scfv clones
    Ai Equibind Different Anti Cd30 Scfv Clones, supplied by Molecular Dynamics Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+cd30/ai+anti+cd30+clones+different+equibind+scfv/pm41709747-48-51-48
    Average 86 stars, based on 1 article reviews
    ai equibind different anti cd30 scfv clones - by Bioz Stars, 2026-09
    86/100 stars
    		  Buy from Supplier
    rabbit anti cd30 antibody  (Cell Signaling Technology Inc)
    93
    Cell Signaling Technology Inc rabbit anti cd30 antibody
    SLFN11 expression in MF/SS and its impact on clinical outcome. ( A ) Representative images of immunohistochemical staining for <t>CD30</t> in skin-infiltrating MF tumor cells (original magnification, scale bar indicating 100 μm). ( B ) Quantification of CD30-positive population (%) in MF/SS tumors using an image analysis software (StrataQuest 7). Representative CD30-negative and -positive results are shown. ( C ) Distribution of CD30-positive population (%) in all cases of MF/SS. A red line indicates a cut-off value at 5%. ( D ) Representative images of immunohistochemical staining for SLFN11 in skin-infiltrating MF tumor cells (top). Vascular endothelial cells in the same sample from Case 13 are positive for SLFN11 (bottom, arrow; original magnification, scale bar indicating 100 μm). ( E ) Quantification of SLFN11-positive population (%) in MF/SS tumors using an image analysis software (StrataQuest 7). Representative SLFN11-negative and -positive results are shown. ( F ) Distribution of SLFN11-positive population (%) in all cases of MF/SS. A red line indicates a cut-off value at 10%. ( G ) Correlation analysis between % of SLFN11-positive (SLFN11 + ) cells and % of CD30-positive (CD30 + ) cells (right) or % of SLFN11 + cells and serum values of sIL-2R (left). Each dot represents one patient. The correlation coefficient ( r ) was calculated using the Pearson correlation coefficient test. ( H ) Kaplan–Meier curves for OS rate (%) in all the enrolled MF/SS patients (25 in MF and 5 in SS patients). For stage IA–IB versus IV, hazard ratio (HR), 0.1183; 95% confidence interval (CI), 0.02969–0.4714; P = .0027 (log-rank test). For stage IIB–III versus IV, HR, 0.1041; 95% CI, 0.02491–0.4350; P = .0046. For stage IA–IB versus IIB–III, HR, 5.755; 95% CI, 0.1096–302.1; P = .3865. ( I ) Kaplan–Meier curves for OS rate (%) in 13 MF/SS patients with stage IV group (8 in SLFN11-positive group and 5 in SLFN11-negative group), HR, 0.7759; 95% CI, 0.1665–3.614; P = .3823. ( J ) Kaplan–Meier curves for OS rate (%) in 13 MF/SS patients with stage IV group (9 in CD30-positive group and 4 in CD30-negative group), HR, 0.7263; 95% CI, 0.1542–3.422; P = .8591. N.S., not significant.
    Rabbit Anti Cd30 Antibody, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+cd30/TNFRSF8%2FCD30+XP+Rabbit+mAb/pmc12501776-91-4-8
    Average 93 stars, based on 1 article reviews
    rabbit anti cd30 antibody - by Bioz Stars, 2026-09
    93/100 stars
    		  Buy from Supplier
    rabbit monoclonal anti cd30  (Cell Signaling Technology Inc)
    86
    Cell Signaling Technology Inc rabbit monoclonal anti cd30
    SLFN11 expression in MF/SS and its impact on clinical outcome. ( A ) Representative images of immunohistochemical staining for <t>CD30</t> in skin-infiltrating MF tumor cells (original magnification, scale bar indicating 100 μm). ( B ) Quantification of CD30-positive population (%) in MF/SS tumors using an image analysis software (StrataQuest 7). Representative CD30-negative and -positive results are shown. ( C ) Distribution of CD30-positive population (%) in all cases of MF/SS. A red line indicates a cut-off value at 5%. ( D ) Representative images of immunohistochemical staining for SLFN11 in skin-infiltrating MF tumor cells (top). Vascular endothelial cells in the same sample from Case 13 are positive for SLFN11 (bottom, arrow; original magnification, scale bar indicating 100 μm). ( E ) Quantification of SLFN11-positive population (%) in MF/SS tumors using an image analysis software (StrataQuest 7). Representative SLFN11-negative and -positive results are shown. ( F ) Distribution of SLFN11-positive population (%) in all cases of MF/SS. A red line indicates a cut-off value at 10%. ( G ) Correlation analysis between % of SLFN11-positive (SLFN11 + ) cells and % of CD30-positive (CD30 + ) cells (right) or % of SLFN11 + cells and serum values of sIL-2R (left). Each dot represents one patient. The correlation coefficient ( r ) was calculated using the Pearson correlation coefficient test. ( H ) Kaplan–Meier curves for OS rate (%) in all the enrolled MF/SS patients (25 in MF and 5 in SS patients). For stage IA–IB versus IV, hazard ratio (HR), 0.1183; 95% confidence interval (CI), 0.02969–0.4714; P = .0027 (log-rank test). For stage IIB–III versus IV, HR, 0.1041; 95% CI, 0.02491–0.4350; P = .0046. For stage IA–IB versus IIB–III, HR, 5.755; 95% CI, 0.1096–302.1; P = .3865. ( I ) Kaplan–Meier curves for OS rate (%) in 13 MF/SS patients with stage IV group (8 in SLFN11-positive group and 5 in SLFN11-negative group), HR, 0.7759; 95% CI, 0.1665–3.614; P = .3823. ( J ) Kaplan–Meier curves for OS rate (%) in 13 MF/SS patients with stage IV group (9 in CD30-positive group and 4 in CD30-negative group), HR, 0.7263; 95% CI, 0.1542–3.422; P = .8591. N.S., not significant.
    Rabbit Monoclonal Anti Cd30, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+cd30/pmc12501776-111-23-33
    Average 86 stars, based on 1 article reviews
    rabbit monoclonal anti cd30 - by Bioz Stars, 2026-09
    86/100 stars
    		  Buy from Supplier
    anti cd30 monoclonal antibody  (Abbott Laboratories)
    86
    Abbott Laboratories anti cd30 monoclonal antibody
    SLFN11 expression in MF/SS and its impact on clinical outcome. ( A ) Representative images of immunohistochemical staining for <t>CD30</t> in skin-infiltrating MF tumor cells (original magnification, scale bar indicating 100 μm). ( B ) Quantification of CD30-positive population (%) in MF/SS tumors using an image analysis software (StrataQuest 7). Representative CD30-negative and -positive results are shown. ( C ) Distribution of CD30-positive population (%) in all cases of MF/SS. A red line indicates a cut-off value at 5%. ( D ) Representative images of immunohistochemical staining for SLFN11 in skin-infiltrating MF tumor cells (top). Vascular endothelial cells in the same sample from Case 13 are positive for SLFN11 (bottom, arrow; original magnification, scale bar indicating 100 μm). ( E ) Quantification of SLFN11-positive population (%) in MF/SS tumors using an image analysis software (StrataQuest 7). Representative SLFN11-negative and -positive results are shown. ( F ) Distribution of SLFN11-positive population (%) in all cases of MF/SS. A red line indicates a cut-off value at 10%. ( G ) Correlation analysis between % of SLFN11-positive (SLFN11 + ) cells and % of CD30-positive (CD30 + ) cells (right) or % of SLFN11 + cells and serum values of sIL-2R (left). Each dot represents one patient. The correlation coefficient ( r ) was calculated using the Pearson correlation coefficient test. ( H ) Kaplan–Meier curves for OS rate (%) in all the enrolled MF/SS patients (25 in MF and 5 in SS patients). For stage IA–IB versus IV, hazard ratio (HR), 0.1183; 95% confidence interval (CI), 0.02969–0.4714; P = .0027 (log-rank test). For stage IIB–III versus IV, HR, 0.1041; 95% CI, 0.02491–0.4350; P = .0046. For stage IA–IB versus IIB–III, HR, 5.755; 95% CI, 0.1096–302.1; P = .3865. ( I ) Kaplan–Meier curves for OS rate (%) in 13 MF/SS patients with stage IV group (8 in SLFN11-positive group and 5 in SLFN11-negative group), HR, 0.7759; 95% CI, 0.1665–3.614; P = .3823. ( J ) Kaplan–Meier curves for OS rate (%) in 13 MF/SS patients with stage IV group (9 in CD30-positive group and 4 in CD30-negative group), HR, 0.7263; 95% CI, 0.1542–3.422; P = .8591. N.S., not significant.
    Anti Cd30 Monoclonal Antibody, supplied by Abbott Laboratories, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+cd30/1+antibody+double+immunoassay+monoclonal+ruo+sandwich+timp/sec_filing____1060736_slash_000119312512088821_slash_d258205d10k-476-46-0
    Average 86 stars, based on 1 article reviews
    anti cd30 monoclonal antibody - by Bioz Stars, 2026-09
    86/100 stars
    		  Buy from Supplier
    anti cd30 antibody program  (Xencor Inc)
    86
    Xencor Inc anti cd30 antibody program
    SLFN11 expression in MF/SS and its impact on clinical outcome. ( A ) Representative images of immunohistochemical staining for <t>CD30</t> in skin-infiltrating MF tumor cells (original magnification, scale bar indicating 100 μm). ( B ) Quantification of CD30-positive population (%) in MF/SS tumors using an image analysis software (StrataQuest 7). Representative CD30-negative and -positive results are shown. ( C ) Distribution of CD30-positive population (%) in all cases of MF/SS. A red line indicates a cut-off value at 5%. ( D ) Representative images of immunohistochemical staining for SLFN11 in skin-infiltrating MF tumor cells (top). Vascular endothelial cells in the same sample from Case 13 are positive for SLFN11 (bottom, arrow; original magnification, scale bar indicating 100 μm). ( E ) Quantification of SLFN11-positive population (%) in MF/SS tumors using an image analysis software (StrataQuest 7). Representative SLFN11-negative and -positive results are shown. ( F ) Distribution of SLFN11-positive population (%) in all cases of MF/SS. A red line indicates a cut-off value at 10%. ( G ) Correlation analysis between % of SLFN11-positive (SLFN11 + ) cells and % of CD30-positive (CD30 + ) cells (right) or % of SLFN11 + cells and serum values of sIL-2R (left). Each dot represents one patient. The correlation coefficient ( r ) was calculated using the Pearson correlation coefficient test. ( H ) Kaplan–Meier curves for OS rate (%) in all the enrolled MF/SS patients (25 in MF and 5 in SS patients). For stage IA–IB versus IV, hazard ratio (HR), 0.1183; 95% confidence interval (CI), 0.02969–0.4714; P = .0027 (log-rank test). For stage IIB–III versus IV, HR, 0.1041; 95% CI, 0.02491–0.4350; P = .0046. For stage IA–IB versus IIB–III, HR, 5.755; 95% CI, 0.1096–302.1; P = .3865. ( I ) Kaplan–Meier curves for OS rate (%) in 13 MF/SS patients with stage IV group (8 in SLFN11-positive group and 5 in SLFN11-negative group), HR, 0.7759; 95% CI, 0.1665–3.614; P = .3823. ( J ) Kaplan–Meier curves for OS rate (%) in 13 MF/SS patients with stage IV group (9 in CD30-positive group and 4 in CD30-negative group), HR, 0.7263; 95% CI, 0.1542–3.422; P = .8591. N.S., not significant.
    Anti Cd30 Antibody Program, supplied by Xencor Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+cd30/anti+antibody+cd30+program/sec_filing____1060736_slash_000119312512088821_slash_d258205d10k-463-20-17
    Average 86 stars, based on 1 article reviews
    anti cd30 antibody program - by Bioz Stars, 2026-09
    86/100 stars
    		  Buy from Supplier
    cd30  (Cell Signaling Technology Inc)
    94
    Cell Signaling Technology Inc cd30
    SLFN11 expression in MF/SS and its impact on clinical outcome. ( A ) Representative images of immunohistochemical staining for <t>CD30</t> in skin-infiltrating MF tumor cells (original magnification, scale bar indicating 100 μm). ( B ) Quantification of CD30-positive population (%) in MF/SS tumors using an image analysis software (StrataQuest 7). Representative CD30-negative and -positive results are shown. ( C ) Distribution of CD30-positive population (%) in all cases of MF/SS. A red line indicates a cut-off value at 5%. ( D ) Representative images of immunohistochemical staining for SLFN11 in skin-infiltrating MF tumor cells (top). Vascular endothelial cells in the same sample from Case 13 are positive for SLFN11 (bottom, arrow; original magnification, scale bar indicating 100 μm). ( E ) Quantification of SLFN11-positive population (%) in MF/SS tumors using an image analysis software (StrataQuest 7). Representative SLFN11-negative and -positive results are shown. ( F ) Distribution of SLFN11-positive population (%) in all cases of MF/SS. A red line indicates a cut-off value at 10%. ( G ) Correlation analysis between % of SLFN11-positive (SLFN11 + ) cells and % of CD30-positive (CD30 + ) cells (right) or % of SLFN11 + cells and serum values of sIL-2R (left). Each dot represents one patient. The correlation coefficient ( r ) was calculated using the Pearson correlation coefficient test. ( H ) Kaplan–Meier curves for OS rate (%) in all the enrolled MF/SS patients (25 in MF and 5 in SS patients). For stage IA–IB versus IV, hazard ratio (HR), 0.1183; 95% confidence interval (CI), 0.02969–0.4714; P = .0027 (log-rank test). For stage IIB–III versus IV, HR, 0.1041; 95% CI, 0.02491–0.4350; P = .0046. For stage IA–IB versus IIB–III, HR, 5.755; 95% CI, 0.1096–302.1; P = .3865. ( I ) Kaplan–Meier curves for OS rate (%) in 13 MF/SS patients with stage IV group (8 in SLFN11-positive group and 5 in SLFN11-negative group), HR, 0.7759; 95% CI, 0.1665–3.614; P = .3823. ( J ) Kaplan–Meier curves for OS rate (%) in 13 MF/SS patients with stage IV group (9 in CD30-positive group and 4 in CD30-negative group), HR, 0.7263; 95% CI, 0.1542–3.422; P = .8591. N.S., not significant.
    Cd30, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+cd30/TNFRSF8%2FCD30+XP+Rabbit+mAb/pm41120574-421-32-33
    Average 94 stars, based on 1 article reviews
    cd30 - by Bioz Stars, 2026-09
    94/100 stars
    		  Buy from Supplier

    Image Search Results


    SLFN11 expression in MF/SS and its impact on clinical outcome. ( A ) Representative images of immunohistochemical staining for CD30 in skin-infiltrating MF tumor cells (original magnification, scale bar indicating 100 μm). ( B ) Quantification of CD30-positive population (%) in MF/SS tumors using an image analysis software (StrataQuest 7). Representative CD30-negative and -positive results are shown. ( C ) Distribution of CD30-positive population (%) in all cases of MF/SS. A red line indicates a cut-off value at 5%. ( D ) Representative images of immunohistochemical staining for SLFN11 in skin-infiltrating MF tumor cells (top). Vascular endothelial cells in the same sample from Case 13 are positive for SLFN11 (bottom, arrow; original magnification, scale bar indicating 100 μm). ( E ) Quantification of SLFN11-positive population (%) in MF/SS tumors using an image analysis software (StrataQuest 7). Representative SLFN11-negative and -positive results are shown. ( F ) Distribution of SLFN11-positive population (%) in all cases of MF/SS. A red line indicates a cut-off value at 10%. ( G ) Correlation analysis between % of SLFN11-positive (SLFN11 + ) cells and % of CD30-positive (CD30 + ) cells (right) or % of SLFN11 + cells and serum values of sIL-2R (left). Each dot represents one patient. The correlation coefficient ( r ) was calculated using the Pearson correlation coefficient test. ( H ) Kaplan–Meier curves for OS rate (%) in all the enrolled MF/SS patients (25 in MF and 5 in SS patients). For stage IA–IB versus IV, hazard ratio (HR), 0.1183; 95% confidence interval (CI), 0.02969–0.4714; P = .0027 (log-rank test). For stage IIB–III versus IV, HR, 0.1041; 95% CI, 0.02491–0.4350; P = .0046. For stage IA–IB versus IIB–III, HR, 5.755; 95% CI, 0.1096–302.1; P = .3865. ( I ) Kaplan–Meier curves for OS rate (%) in 13 MF/SS patients with stage IV group (8 in SLFN11-positive group and 5 in SLFN11-negative group), HR, 0.7759; 95% CI, 0.1665–3.614; P = .3823. ( J ) Kaplan–Meier curves for OS rate (%) in 13 MF/SS patients with stage IV group (9 in CD30-positive group and 4 in CD30-negative group), HR, 0.7263; 95% CI, 0.1542–3.422; P = .8591. N.S., not significant.

    Journal: NAR Cancer

    Article Title: Co-expression of CD30 and SLFN11 serves as a dual biomarker for the treatment of cutaneous T-cell lymphoma

    doi: 10.1093/narcan/zcaf037

    Figure Lengend Snippet: SLFN11 expression in MF/SS and its impact on clinical outcome. ( A ) Representative images of immunohistochemical staining for CD30 in skin-infiltrating MF tumor cells (original magnification, scale bar indicating 100 μm). ( B ) Quantification of CD30-positive population (%) in MF/SS tumors using an image analysis software (StrataQuest 7). Representative CD30-negative and -positive results are shown. ( C ) Distribution of CD30-positive population (%) in all cases of MF/SS. A red line indicates a cut-off value at 5%. ( D ) Representative images of immunohistochemical staining for SLFN11 in skin-infiltrating MF tumor cells (top). Vascular endothelial cells in the same sample from Case 13 are positive for SLFN11 (bottom, arrow; original magnification, scale bar indicating 100 μm). ( E ) Quantification of SLFN11-positive population (%) in MF/SS tumors using an image analysis software (StrataQuest 7). Representative SLFN11-negative and -positive results are shown. ( F ) Distribution of SLFN11-positive population (%) in all cases of MF/SS. A red line indicates a cut-off value at 10%. ( G ) Correlation analysis between % of SLFN11-positive (SLFN11 + ) cells and % of CD30-positive (CD30 + ) cells (right) or % of SLFN11 + cells and serum values of sIL-2R (left). Each dot represents one patient. The correlation coefficient ( r ) was calculated using the Pearson correlation coefficient test. ( H ) Kaplan–Meier curves for OS rate (%) in all the enrolled MF/SS patients (25 in MF and 5 in SS patients). For stage IA–IB versus IV, hazard ratio (HR), 0.1183; 95% confidence interval (CI), 0.02969–0.4714; P = .0027 (log-rank test). For stage IIB–III versus IV, HR, 0.1041; 95% CI, 0.02491–0.4350; P = .0046. For stage IA–IB versus IIB–III, HR, 5.755; 95% CI, 0.1096–302.1; P = .3865. ( I ) Kaplan–Meier curves for OS rate (%) in 13 MF/SS patients with stage IV group (8 in SLFN11-positive group and 5 in SLFN11-negative group), HR, 0.7759; 95% CI, 0.1665–3.614; P = .3823. ( J ) Kaplan–Meier curves for OS rate (%) in 13 MF/SS patients with stage IV group (9 in CD30-positive group and 4 in CD30-negative group), HR, 0.7263; 95% CI, 0.1542–3.422; P = .8591. N.S., not significant.

    Article Snippet: Sections were incubated with rabbit anti-CD30 antibody (1:200; Cell Signaling Technology, #54 535, clone E4L4I) and mouse anti-SLFN11 antibody (D-2) at RT for 1 h. After washing, the slides were incubated with matched secondary antibodies, Alexa Fluor 594 donkey anti-mouse IgG and Alexa Fluor 488 donkey anti-rabbit IgG (1:200; Thermo Fisher Scientific), for 30 min at RT, then washed and mounted with Mounting Medium with DAPI (Thermo Fisher Scientific).

    Techniques: Expressing, Immunohistochemical staining, Staining, Software

    Co-expression of SLFN11 and CD30 in MF tumor cells. ( A ) Representative images of immunohistochemical staining for SLFN11 and CD30 in skin-infiltrating MF tumor cells (original magnification, scale bar indicating 100 μm). ( B ) Representative images of immunofluorescence staining for SLFN11 (red), CD30 (green), and DAPI (blue) corresponding to Fig. (original magnification, scale bar indicating 100 μm). ( C ) An image cytometry analysis by StrataQuest 7 shows the intensity of SLFN11 and CD30 in each cell.

    Journal: NAR Cancer

    Article Title: Co-expression of CD30 and SLFN11 serves as a dual biomarker for the treatment of cutaneous T-cell lymphoma

    doi: 10.1093/narcan/zcaf037

    Figure Lengend Snippet: Co-expression of SLFN11 and CD30 in MF tumor cells. ( A ) Representative images of immunohistochemical staining for SLFN11 and CD30 in skin-infiltrating MF tumor cells (original magnification, scale bar indicating 100 μm). ( B ) Representative images of immunofluorescence staining for SLFN11 (red), CD30 (green), and DAPI (blue) corresponding to Fig. (original magnification, scale bar indicating 100 μm). ( C ) An image cytometry analysis by StrataQuest 7 shows the intensity of SLFN11 and CD30 in each cell.

    Article Snippet: Sections were incubated with rabbit anti-CD30 antibody (1:200; Cell Signaling Technology, #54 535, clone E4L4I) and mouse anti-SLFN11 antibody (D-2) at RT for 1 h. After washing, the slides were incubated with matched secondary antibodies, Alexa Fluor 594 donkey anti-mouse IgG and Alexa Fluor 488 donkey anti-rabbit IgG (1:200; Thermo Fisher Scientific), for 30 min at RT, then washed and mounted with Mounting Medium with DAPI (Thermo Fisher Scientific).

    Techniques: Expressing, Immunohistochemical staining, Staining, Immunofluorescence, Cytometry

    Activation via T-cell receptor/IL-2R induces the functional SLFN11 expression in normal T cells. ( A ) Immunoblotting showing SLFN11, CD30, and CD3 expressions in PBMCs with or without IFN-γ or CD3/CD28/IL-2 stimulation for 5 days. Actin was used as a loading control. ( B ) Representative confocal microscopy images for SLFN11 (green), CD3 (red), and DAPI (blue) (top panel) or SLFN11 (green), CD30 (red), and DAPI (blue) (bottom panel) in PBMCs 7 days after each activation (original magnification, scale bar indicating 10 μm). ( C ) Viability curves to various concentrations of TOP1 inhibitor CPT in PBMCs with or without CD3/CD28/IL-2 stimulation for 5–7 days. Viability was examined by ATP assay 48 h after the CPT treatments. Representative results in triplicate from two independent experiments are shown as mean ± SD.

    Journal: NAR Cancer

    Article Title: Co-expression of CD30 and SLFN11 serves as a dual biomarker for the treatment of cutaneous T-cell lymphoma

    doi: 10.1093/narcan/zcaf037

    Figure Lengend Snippet: Activation via T-cell receptor/IL-2R induces the functional SLFN11 expression in normal T cells. ( A ) Immunoblotting showing SLFN11, CD30, and CD3 expressions in PBMCs with or without IFN-γ or CD3/CD28/IL-2 stimulation for 5 days. Actin was used as a loading control. ( B ) Representative confocal microscopy images for SLFN11 (green), CD3 (red), and DAPI (blue) (top panel) or SLFN11 (green), CD30 (red), and DAPI (blue) (bottom panel) in PBMCs 7 days after each activation (original magnification, scale bar indicating 10 μm). ( C ) Viability curves to various concentrations of TOP1 inhibitor CPT in PBMCs with or without CD3/CD28/IL-2 stimulation for 5–7 days. Viability was examined by ATP assay 48 h after the CPT treatments. Representative results in triplicate from two independent experiments are shown as mean ± SD.

    Article Snippet: Sections were incubated with rabbit anti-CD30 antibody (1:200; Cell Signaling Technology, #54 535, clone E4L4I) and mouse anti-SLFN11 antibody (D-2) at RT for 1 h. After washing, the slides were incubated with matched secondary antibodies, Alexa Fluor 594 donkey anti-mouse IgG and Alexa Fluor 488 donkey anti-rabbit IgG (1:200; Thermo Fisher Scientific), for 30 min at RT, then washed and mounted with Mounting Medium with DAPI (Thermo Fisher Scientific).

    Techniques: Activation Assay, Functional Assay, Expressing, Western Blot, Control, Confocal Microscopy, ATP Assay

    JAK pathway activation and epigenetic suppression regulate SLFN11 expression in CTCL cell lines. ( A ) Immunoblotting showing SLFN11 and CD30 expressions in HUT78 cells treated with pan-JAK inhibitor, cerdulatinib (40 μM), for the indicated time. Actin was used as a loading control. A representative result of two independent experiments is shown. ( B ) Immunoblotting showing SLFN11 expression in MJ cells treated with the indicated HDAC inhibitors (10 μM each) for 16 h. GAPDH was used as a loading control. The relative ratio of SLFN11/GAPDH in each HDAC inhibitor-treated MJ cell is indicated at the bottom. A representative result of three independent experiments is shown. ( C ) Viability curves of the MJ cells to the indicated HDAC inhibitors. Viability was examined by ATP assay 72 h after the drug treatments. Representative results in triplicate from two independent experiments are shown as mean ± SD.

    Journal: NAR Cancer

    Article Title: Co-expression of CD30 and SLFN11 serves as a dual biomarker for the treatment of cutaneous T-cell lymphoma

    doi: 10.1093/narcan/zcaf037

    Figure Lengend Snippet: JAK pathway activation and epigenetic suppression regulate SLFN11 expression in CTCL cell lines. ( A ) Immunoblotting showing SLFN11 and CD30 expressions in HUT78 cells treated with pan-JAK inhibitor, cerdulatinib (40 μM), for the indicated time. Actin was used as a loading control. A representative result of two independent experiments is shown. ( B ) Immunoblotting showing SLFN11 expression in MJ cells treated with the indicated HDAC inhibitors (10 μM each) for 16 h. GAPDH was used as a loading control. The relative ratio of SLFN11/GAPDH in each HDAC inhibitor-treated MJ cell is indicated at the bottom. A representative result of three independent experiments is shown. ( C ) Viability curves of the MJ cells to the indicated HDAC inhibitors. Viability was examined by ATP assay 72 h after the drug treatments. Representative results in triplicate from two independent experiments are shown as mean ± SD.

    Article Snippet: Sections were incubated with rabbit anti-CD30 antibody (1:200; Cell Signaling Technology, #54 535, clone E4L4I) and mouse anti-SLFN11 antibody (D-2) at RT for 1 h. After washing, the slides were incubated with matched secondary antibodies, Alexa Fluor 594 donkey anti-mouse IgG and Alexa Fluor 488 donkey anti-rabbit IgG (1:200; Thermo Fisher Scientific), for 30 min at RT, then washed and mounted with Mounting Medium with DAPI (Thermo Fisher Scientific).

    Techniques: Activation Assay, Expressing, Western Blot, Control, ATP Assay